BR112012002102A2 - composição farmaceutica e metodo para preparar uma composição farmaceutica - Google Patents

composição farmaceutica e metodo para preparar uma composição farmaceutica

Info

Publication number
BR112012002102A2
BR112012002102A2 BR112012002102A BR112012002102A BR112012002102A2 BR 112012002102 A2 BR112012002102 A2 BR 112012002102A2 BR 112012002102 A BR112012002102 A BR 112012002102A BR 112012002102 A BR112012002102 A BR 112012002102A BR 112012002102 A2 BR112012002102 A2 BR 112012002102A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
pharmaceutical
composition
Prior art date
Application number
BR112012002102A
Other languages
English (en)
Inventor
Schneider Anneliese
Jaschinski Frank
Schlingensiepen Karl-Hermann
Original Assignee
Antisense Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012002102(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antisense Pharma Gmbh filed Critical Antisense Pharma Gmbh
Publication of BR112012002102A2 publication Critical patent/BR112012002102A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
BR112012002102A 2009-07-30 2010-07-30 composição farmaceutica e metodo para preparar uma composição farmaceutica BR112012002102A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09166893 2009-07-30
PCT/EP2010/061152 WO2011012713A1 (en) 2009-07-30 2010-07-30 Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system

Publications (1)

Publication Number Publication Date
BR112012002102A2 true BR112012002102A2 (pt) 2017-05-02

Family

ID=41278403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002102A BR112012002102A2 (pt) 2009-07-30 2010-07-30 composição farmaceutica e metodo para preparar uma composição farmaceutica

Country Status (17)

Country Link
US (1) US8476246B2 (pt)
EP (1) EP2340308B1 (pt)
JP (1) JP2013500313A (pt)
KR (1) KR20120107456A (pt)
CN (1) CN102712924A (pt)
AU (1) AU2010277554B2 (pt)
BR (1) BR112012002102A2 (pt)
CA (1) CA2769618A1 (pt)
CL (1) CL2012000247A1 (pt)
CO (1) CO6511199A2 (pt)
EC (1) ECSP12011689A (pt)
IL (1) IL217821A0 (pt)
IN (1) IN2012DN00969A (pt)
MX (1) MX2012001244A (pt)
PE (1) PE20121495A1 (pt)
RU (1) RU2012107535A (pt)
WO (1) WO2011012713A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60322509D1 (de) * 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
TWI454281B (zh) * 2011-10-06 2014-10-01 Nat Univ Tsing Hua 硼酸於硼中子捕獲治療肝癌之用途
WO2013124869A2 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
CA2903239A1 (en) * 2013-03-14 2014-10-02 Oncogenex Technologies Inc. Custirsen treatment with reduced toxicity
US10386359B2 (en) * 2014-05-23 2019-08-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining whether a patient will achieve a response after radiation therapy
US11759530B2 (en) * 2014-11-17 2023-09-19 City Of Hope TKI permeability enhancers
EP3314250A4 (en) 2015-06-26 2018-12-05 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
CA3090652A1 (en) 2018-02-06 2019-08-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
US20220145304A1 (en) * 2019-03-14 2022-05-12 The Research Foundation For The State University Of New York Modified micrornas and their use in the treatment of cancer
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
CN112933238A (zh) * 2021-02-02 2021-06-11 石河子大学 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用
CN113425855B (zh) * 2021-06-28 2023-11-07 深圳瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0856579A1 (en) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
CN1845733A (zh) * 2003-09-04 2006-10-11 学校法人日本大学 TGF－β基因表达抑制剂
ZA200602941B (en) * 2003-11-13 2007-07-25 Genentech Inc Screening assays and methods of tumor treatment
WO2005050200A2 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
CA2550058C (en) * 2003-12-19 2016-07-12 Antisense Pharma Gmbh Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
JPWO2007088651A1 (ja) * 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
JP5322476B2 (ja) * 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法

Also Published As

Publication number Publication date
JP2013500313A (ja) 2013-01-07
RU2012107535A (ru) 2013-09-10
US20120027873A1 (en) 2012-02-02
EP2340308A1 (en) 2011-07-06
EP2340308B1 (en) 2014-12-24
CL2012000247A1 (es) 2013-07-05
AU2010277554B2 (en) 2015-02-19
KR20120107456A (ko) 2012-10-02
CA2769618A1 (en) 2011-02-03
MX2012001244A (es) 2012-03-26
AU2010277554A1 (en) 2012-03-01
IN2012DN00969A (pt) 2015-04-10
IL217821A0 (en) 2012-03-29
US8476246B2 (en) 2013-07-02
CN102712924A (zh) 2012-10-03
ECSP12011689A (es) 2012-06-29
CO6511199A2 (es) 2012-08-31
PE20121495A1 (es) 2012-11-19
WO2011012713A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112012009609A2 (pt) método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BR112014015042A8 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI1012148A2 (pt) método e equipamento para preparar dentadura
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI0921659A2 (pt) metodo e sistema para formar uma protese dentaria
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI1004940A2 (pt) composição farmacêutica
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
ES2580777T8 (es) Composición farmacéutica sólida que comprende amlodipino y losartán y procedimiento para producir la misma
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI1015541A2 (pt) kit e método para a preparação de uma solução de degarelix
BRPI1015095A2 (pt) composição, processos para preparar uma composição e um material de poli-isocianurato , e, material de poli-isocianurato
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BR112012031033A2 (pt) composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina
BRPI1006895A2 (pt) método e aparelho para suportar uma carga
BRPI1015939A2 (pt) composição farmacêutica
BRPI1007160A2 (pt) Método para esterilizar um material
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]